Skip to content
OpenCapital
Get started

AbbVie ABBV Venclexta — Net revenues

Other product segments

Skyrizi
$4.48B+30.9%
Rinvoq
$2.12B+23.3%
All other
$1.03B-18.2%
Botox Therapeutic
$1.01B+16.5%
Vraylar
$905M+18.3%
Humira
$688M-38.6%
Botox Cosmetic
$668M+20.1%
Imbruvica
$556M-24.7%
Mavyret
$351M+14.7%
Ubrelvy
$339M+41.3%
Qulipta
$296M+53.4%
Other Aesthetics
$286M-9.2%
Linzess
$283M+91.2%
Juvederm Collection
$232M+0.4%
Vyalev
$201M+219%
Elahere
$198M+10.6%
Other Neuroscience
$125M-19.4%
Epkinly
$83M+62.7%

Similar metrics at other companies

Eli Lilly logo
LLYVerzenio — Revenue
$1.3B+12.3%
Jazz Pharmaceuticals logo
JAZZVyxeos — Revenue from Contract with Customer, Excluding Assessed Tax
$26.6M-9.8%
Amgen logo
AMGNVectibix — Total revenues
$287M+7.5%
Ligand Pharmaceuticals logo
LGNDVaxneuvance — Total revenues and income
$1.61M+25.3%
Gilead Sciences logo
GILDVeklury — Total revenues
$144M-52.3%
Gilead Sciences logo
GILDGenvoya — Total revenues
$264M-27.5%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$465.2B+39.1%
P/E128×+39.1×
P/S7.4×+1.7×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%—
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's venclexta — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's venclexta — net revenues?
AbbVie (ABBV) reported venclexta — net revenues of $770M in Q1 2026.
How has AbbVie's venclexta — net revenues changed year-over-year?
AbbVie's venclexta — net revenues increased by 15.8% year-over-year, from $665M to $770M.
What is the long-term trend for AbbVie's venclexta — net revenues?
Over 4 years (2021 to 2025), AbbVie's venclexta — net revenues has grown at a 11.3% compound annual growth rate (CAGR), from $1.82B to $2.79B.
What does venclexta — net revenues mean?
This metric represents the total gross sales of a specific oncology pharmaceutical product, adjusted for returns, allowances, and rebates. It reflects the market adoption and commercial performance of the drug within the company's hematology-oncology portfolio. Monitoring this revenue stream provides insight into the product's lifecycle, competitive positioning in the cancer treatment market, and its contribution to the firm's overall therapeutic growth.